Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential

  • Authors:
    • Ting Huyan
    • Qi Li
    • Dan‑Dan Dong
    • Hui Yang
    • Xiao‑Ping Xue
    • Qing‑Sheng Huang
  • View Affiliations

  • Published online on: January 25, 2017     https://doi.org/10.3892/ol.2017.5642
  • Pages: 1539-1546
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human aspartyl-(asparaginyl)-β-hydroxylase (HAAH) has recently been the subject of several studies, as it was previously observed to be overexpressed in numerous types of carcinoma cells and tissues in patient tumor samples. HAAH has been implicated in tumor invasion and metastasis, indicating that it may be an important target and biomarker for tumor diagnosis and treatment. However, the immunological tools currently available for the study of this protein, including monoclonal antibodies, are limited, as is the present knowledge regarding the role of HAAH in tumor therapy and diagnosis. In the present study, a recombinant C‑terminal domain of HAAH was expressed in Pichia pastoris and a novel monoclonal antibody (mAb) targeting HAAH (HAAH‑C) was constructed. Immunofluorescence and antibody‑dependent cellular cytotoxicity (ADCC) assays were used to demonstrate the specificity and ADCC activity of this antibody. The results demonstrated that this anti‑C‑terminal HAAH mAB, in combination with an existing anti‑N terminal HAAH mAb, exhibited a high response to native HAAH from carcinoma cell culture supernatant, as measured with a double antibody sandwich enzyme‑linked immunosorbent assay. This validated novel mAB‑HAAH‑C may prompt further studies into the underlying mechanisms of HAAH, and the exploration of its potential in tumor diagnosis and therapy.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huyan T, Li Q, Dong DD, Yang H, Xue XP and Huang QS: Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential. Oncol Lett 13: 1539-1546, 2017.
APA
Huyan, T., Li, Q., Dong, D., Yang, H., Xue, X., & Huang, Q. (2017). Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential. Oncology Letters, 13, 1539-1546. https://doi.org/10.3892/ol.2017.5642
MLA
Huyan, T., Li, Q., Dong, D., Yang, H., Xue, X., Huang, Q."Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential". Oncology Letters 13.3 (2017): 1539-1546.
Chicago
Huyan, T., Li, Q., Dong, D., Yang, H., Xue, X., Huang, Q."Development of a novel anti-human aspartyl-(asparaginyl) β-hydroxylase monoclonal antibody with diagnostic and therapeutic potential". Oncology Letters 13, no. 3 (2017): 1539-1546. https://doi.org/10.3892/ol.2017.5642